ERBB2 and gastric cancer: Combination of human epidermal growth factor receptor 2 (HER2) inhibitor pyrotinib and CDK4/6 inhibitor SHR6390 was thought to be a more effective treatment strategy for HER2-positive metastatic GC (171).